tbuckley/cabot-search huggingface dataset:
CLINICAL EFFECTIVENESS OF SPIRONOLACTONE IN HOSPITALIZED OLDER ELIGIBLE (EF LESS THAN OR EQUAL TO 35% AND EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M2) PATIENTS WITH HEART FAILURE
Authors: Daniel Dooley, Phillip Lam, Essraa Bayoumi, Jonathan Segal, Cherinne Arundel, Gerasimos Filippatos, Javed Butler, Prakash Deedwania, Michel White, Marc Blackman, Charity Morgan, Spyridon Deftereos, Wilbert Aronow, Stefan Anker, Bertram Pitt, Gregg Fonarow, Ali Ahmed
Journal: Journal of the American College of Cardiology (2017)
Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease.
Authors: Li Zhou, Christine McMahon, Tushar Bhagat, Christina Alencar, Yiting Yu, M. Fazzari, Davendra P. Sohal, Krishna Gundabolu, Chun Ng, Yongkai Mo, Amittha Wickrema, G. Kong, Ellen Friedman, Lubomir Sokol, Pearlie K Burnette, Ulrich Steidl, L. Yan, Jm Yingling, MM Lahn, Alan F List, Markus Bitzer, Amit Verma
Journal: Blood (2009)
Photosensitizer uptake, tumor oxygenation and clinical outcome in a phase II trial of photofrin (PF)-mediated intraperitoneal photodynamic therapy (IP PDT)
Authors: S. M. Hahn, D. L. Fraker, R. Mick, J. Metz, T. Zhu, C. Menon, T. M. Busch, D. Shin, S. M. Evans, E. Glatstein
Journal: Journal of Clinical Oncology (2004)

3723 Background: Disseminated carcinomatosis/sarcomatosis is incurable. Response and survival rates after standard therapies are dismal. Methods: We conducted a phase II trial of PF-mediated IP PDT and debulking surgery (d-surgery) in patients (pts) with IP malignancies. A unique aspect of this trial was the prospective measurement of tumor & normal tissue PF uptake and tumor oxygenation (EF-5 [2-nitroimidazole] binding). Pts were stratified by tumor type: ovarian, GI, & sarcoma. Failure (disease persistence), survival and toxicity were also evaluated. Pts received PF 2.5 mg/kg IV 2 days prior to d-surgery and intraoperative laser light delivery to peritoneal surfaces. Results: From 5/97–12/02, 100 pts (ovarian 33, GI 37, sarcoma 30) enrolled and received PF. 71 pts underwent d-surgery and light delivery (ovarian 23, GI 22, sarcoma 26). Reasons for exclusion were unresectable, localized only, or no evidence of disease. At 42 mos median follow-up, 52 of 71 pts who received PDT have died. Median failure-free survival (FFS) and overall survival (OS), respectively, were: ovarian 3.0 & 19.7 mos, GI 3.3 & 13.2 mos, and sarcoma 4.0 & 21.9 mos. Capillary leak syndrome was the major but reversible toxicity necessitating massive volume resuscitation and ICU monitoring. There were two post-surgery deaths due to myocardial infarction and bleeding/sepsis. PF tumor levels (10 pts) ranged from 2.0–5.3 ng/mg in ovarian, 0.13–6.7 in GI, and 0.96–3.28 in sarcoma. Physiological to severe hypoxia was observed in GI and ovarian tumors (N=7) but colon carcinoma demonstrated the largest percentage of tumor specimens with moderate to severe hypoxia. Conclusions: This phase II trial of IP PDT for IP malignancies showed manageable toxicity, extended OS yet persistence of IP disease and brief FFS. We speculate that the disparity between FFS and OS may be due to notable decreased tumor burden. The correlative studies showed heterogeneity in PF and oxygen levels which has implications for pt selection. IP PDT is feasible, but hypoxia and issues related to photosensitizer uptake should be addressed in future trials. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Axcan Scandipharm
MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL
Authors: Robert Sanchez, Khurram Nasir, Alexa Klimchak, Andreas Kuznik, Florence Joulain, Andrew Briggs
Journal: Journal of the American College of Cardiology (2017)
Finding an effective dose of fentanyl effervescent buccal tablets: Combined results of open-label titration
Authors: M. S. Wertheim, H. Jhangiani, G. Niebler, V. Charu
Journal: Journal of Clinical Oncology (2006)

18521 Background: Standard recommendations for short-acting oral opioid doses to manage breakthrough pain (BTP) assume some relation with the stable opioid dose used to treat persistent pain. Fentanyl effervescent buccal tablets (FEBT) are designed to enhance the efficiency of fentanyl absorption through the buccal mucosa. They may provide rapid-onset analgesia. This pooled analysis of data from 3 studies examined the relationship between effective FEBT dose and around-the-clock (ATC) dose in patients who completed open-label titration to an effective FEBT dose. Methods: Patients were 18–80 years of age with cancer, persistent pain, and BTP. Eligible patients experienced an average of 1–4 episodes of BTP per day and were receiving stable doses of opioids (≥60 mg/day of morphine or equivalent) for persistent pain. Titration guidelines were uniform across studies; the maximum allowed dose of FEBT was 800 μg. Results: Of 304 patients enrolled, 208 completed titration to an effective FEBT dose; of these, 100 μg was effective in 21 patients, 200 μg in 32, 400 μg in 45, 600 μg in 49, and 800 μg in 61. The effective dose of FEBT showed no relationship to the dose of either ATC or supplemental opioids. No correlation was found between the effective dose of FEBT and the average dose of prior supplemental opioids (r 2 = .0322; Pearson’s coefficient = .1793), the effective dose of FEBT and the dose of ATC opioids in patients using oral ATC opioids (r 2 = .0353; Pearson’s coefficient = .1878), or the effective dose of FEBT and the dose of ATC opioids in patients using transdermal fentanyl alone or in combination with other opioids as ATC medication (r 2 = .0289; Pearson’s coefficient = .1701). Conclusions: No predictable relationship between the effective dose of FEBT and the dose of ATC opioids was observed. Titration will allow the identification of each patient’s effective dose of FEBT for relief of BTP. [Table: see text]
Canadian cost comparison of different forms of androgen ablative therapies prior and during the castration-resistant prostate cancer.
Authors: Alice Dragomir, Marie Vanhuyse, Fabio L. Cury, Armen G. Aprikian
Journal: Journal of Clinical Oncology (2014)

e16029 Background: Medical or surgical castration are the treatments of choice for hormone-sensitive prostate cancer with a high-risk of disease recurrence or progression. In addition, androgen ablation (ADT) maintenance is recommended during the castration-resistant prostate cancer phase. The objective of this study was to perform a cost comparison of different ADT forms, including luteinizing hormone releasing hormone agonists (LHRHa) medications and surgical castration, given prior to and during the castration-resistant prostate cancer (CRPC) phase. Methods: A Markov model was developed in order to simulate survival since ADT initiation and associated costs as per Quebec’s public healthcare system, in patients with a high-risk of disease recurrence or progression. The model includes recently approved additional lines of treatment given after docetaxel (i.e. abiraterone and cabazitaxel). Survival was based on clinical trial results and clinical practice guidelines found through a literature review. Costs are in 2014 Canadian dollars ($). Results: The mean per patient ADT cost in CRPC over an average period of 28.1 months was estimated at: $1,413 for surgical castration, $8,346 for Leuprolide (Eligard), $8,514 for Triptorelin (Trelstar), $9,891 for Buserelin (Suprefact Depot), $10,032 Leuprolide (Lupron Depot), and $10,172 for Goserelin (Zoladex). The corresponding values in the period prior to CRPC, over 75.1 months, were: $1,413, $22,305, $22,755, $26,435, $26,811 and $27,186, respectively. For each annual Canadian cohort of 4,000 CRPC patients, the total cost of ADT during the CRPC phase was estimated at $5.6 million for surgical castration, and between $33.4 and $40.7 million for LHRHa therapy. Over the period prior to CRPC, the total cost for surgical castration remained the same and was between $89.2 and $108.8 million for LHRHa therapy. Conclusions: Our study estimates the costs associated with the use of different ADT prior and over the CRPC phase. Increasing the use of least costly forms of ADT will result in potential cost savings.
LONG-TERM OUTCOME OF PULMONARY VEIN ISOLATION WITH AND WITHOUT FOCAL IMPULSE AND ROTOR MODULATION (FIRM) MAPPING: RESULTS FROM A META-ANALYSIS
Authors: Sanghamitra Mohanty, Prasant Mohanty, Carola Gianni, Chintan Trivedi, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2017)
The First International Congress of Group Psychotherapy
Authors: Berthold Stokvis, Berthold Stokvis, S. Lebovici, Weixman J. Warner, Joshua Bierer, S.H. Foulkes, Samuel B. Hadden, Wilfred C. Hulse, J.L. Moreno, S.R. Slavson, Zerka T. Moreno, R. Schindler, Berthold Stokvis, H.R. Teirich, F. Tosquelles, R. Gentis, M. Enkin, F. Bonnet
Journal: Psychotherapy and Psychosomatics (1959)
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).
Authors: Julien Taïeb, Josep Tabernero, Enrico Mini, Fabien Subtil, Gunnar Folprecht, Jean-Luc Van Laethem, Joseph Thaler, John A. Bridgewater, Evaristo Sanches, Lone Petersen, Laurence Collette, Eric Van Cutsem, Karine Le Malicot, Philippe Rougier, Ramon Salazar, Laurent Bedenne, Jean Francois Emile, Pierre Laurent-Puig, Come Lepage
Journal: Journal of Clinical Oncology (2013)

3525^ Background: Potential benefit of adding CTX to the current standard treatment for stage III CC, was assessed. Subgroup analyses of demographic, clinical and molecular data may improve our understanding of this patient population. Methods: Patients (pts) were randomized 28-56 days following resection. They received 12 biweekly cycles of oxaliplatin 85 mg/m 2 day (d) 1, with leucovorin 200 mg/m 2 , 5-FU 400 mg/m 2 bolus IV, followed by 5-FU 600 mg/m 2 22-hr IV on d1-2 (FOLFOX4), without (arm A) or with weekly CTX (arm B) 250 mg/m 2 (initial dose 400 mg/m 2 ). Primary endpoint was disease free survival time (DFS). Secondary endpoints included overall survival (OS), treatment compliance and safety. Enrolment was restricted to KRAS wt pts in 06/2008. Planned accrual of 1,407 KRAS wild-type (wt) pts provided 90% power to detect a hazard ratio (HR) of 0.75 with 2-sided α=0.05, with interim analyses after 65% of planned events. Preplanned subgroup analyses were performed. Results: 1,602 KRAS wt pts (811 arm A, 791 arm B) and 742 mutated (m) KRAS (prior to the amendment), were randomized. BRAF status was determined in 1134 (71%) KRAS wt pts. Median follow-up was 40 months. This interim analysis showed no difference between arms for DFS (HR 1.05, 95% CI 0.85-1.29; p=0.66) or OS (HR 1.09, 95% CI 0.81-1.47; p=0.55) in KRAS wt pts or for DFS (HR 0.99, 95% CI 0.75-1.28; p=0.91) or OS (HR 0.98, 95% CI 0.67-1.44; p=0.92) in KRAS/BRAF wt pts (n=984). Similar results were seen in KRAS mutant (mt) pts without any detrimental effect. In KRAS wt pts worse outcomes were seen with CTX in pts &gt;70 years (n=149, DFS: HR 1.97, 95% CI 0.99-3.93; p=0.05), in females (n=666, HR 1.45, 95% CI 1.03-2.03; p=0.03) and in pts with right-sided CC (n=570, HR 1.40, 95% CI 1.01-1.94; p=0.04). Conversely, a better outcome was seen in pts with pT4pN2 CC (n=146, HR 0.55, 95% CI 0.35-0.89; p=0.01). Conclusions: Adding CTX to FOLFOX4 offered no benefit to pts with resected stage III KRAS wt, KRAS/BRAF wt and KRAS mt CC. Subgroup analyses suggest that KRAS wt pts with pT4pN2 tumors may derive benefit from CTX. MSI status determination is ongoing to explore its potential interaction with poor outcome in female and/or with right-sided tumors pts. Clinical trial information: NCT00265811.
STAIR STEP TEST AND SITTING RISING CHAIR TEST AS PREDICTORS OF MAXIMAL OXIGEN UPTAKE
Authors: Luiz Eduardo Fonteles Ritt, Jessica Porto, Thaissa Claro, Daniela Cavalcante, Cristiane M. Feitosa, Eloisa Prado, Gustavo F. Feitosa, Eduardo Darze
Journal: Journal of the American College of Cardiology (2017)
The Technology Enhanced Navigation (TEN) Trial among low-income patients with breast cancer.
Authors: Kathy J. Helzlsouer, Susan Appling, Susan Scarvalone, Shannon Manocheh, Lisa Gallicchio, Ryan MacDonald, Dawn Henninger, Arti Varanasi
Journal: Journal of Clinical Oncology (2015)

6500 Background: Socioeconomic disparities negatively impact adjuvant breast cancer treatment completion. A web-based knowledge application was developed in collaboration with breast cancer survivors and evaluated in a randomized clinical trial for the impact on treatment adherence with and without virtual navigator support. The application provides direct links to vetted websites for both study arms, and, for the intervention arm, tailored documents, short instructional videos, and navigator visits via videoconference or phone are provided. Methods: Eligible patients were newly diagnosed with non-metastatic breast cancer, low-income (U.S. Department of Housing and Urban Development guidelines) Maryland residents, and recommended to have adjuvant treatment. Patients were given a netbook computer, training, and 12 months of wireless Internet access and randomized to either the application alone (control arm) or to the application and nurse/social worker navigation support (intervention arm). Adherence was assessed by medical record review and measured by percent initiating/completing recommended treatment. Baseline characteristics and results were compared by study arm using t-tests, chi-square, and Poisson regression analyses. Results: Of 150 eligible patients, 101 were enrolled; 49 on each arm evaluable. The majority were non-white (67%) and unemployed/on disability (68%); 47% had a high school education or less. Over 70% of participants on both arms agreed that the computer application was easy to use; confidence in using the application was high (71% intervention arm; 67% control arm). On the control arm, 10 adjuvant treatments were refused totally or in part among 6 patients; 2 on the intervention arm (p = 0.04). Three control-arm patients refused multiple treatments: one refused surgery and radiation; another refused radiation and hormone therapies and discontinued chemotherapy; another refused chemotherapy and hormone therapy. One patient on the intervention arm refused post-mastectomy radiation and another completed chemotherapy, initiated hormone therapy, but discontinued radiation therapy. Conclusions: Among low-income patients with breast cancer, adherence to adjuvant therapy was improved with navigator support compared to application-access alone. Clinical trial information: NCT01596179.
Expression levels of PARP1 and phospho-p65 protein in human HER2-positive breast cancers.
Authors: Jennifer Anne Stanley, Lisa Caroline Klepczyk, Kimberly Sue Keene, Shi Wei, Yufeng Li, Andres Forero-Torres, William E. Grizzle, Monica Wielgos, Jason D. Brazelton, Albert F. LoBuglio, Eddy Shih-Hsin Yang
Journal: Journal of Clinical Oncology (2015)

601 Background: Previous studies have shown that basal breast cancers, which may have an inherent “BRCAness” phenotype and sensitivity to inhibitors of poly (ADP-Ribose) polymerase (PARP), express elevated levels of PARP1. Our lab previously reported that HER2+ breast cancers are exquisitely sensitive to PARP inhibitors (PARPi) thru alteration of the NF-kB pathway. In this study, we assessed levels of PARP1 and phospho-p65, a marker of activated NF-kB, in human breast cancer tissues. Methods: PARP1 and PARP2 copy number, mRNA, and protein expression were assessed by interrogating the PAM-50 defined breast cancer patient set from the TCGA using the cBioPortal. PARP1 and phospho-p65 immunohistochemistry and correlation to clinical parameters were conducted using 307 primary breast cancer specimens (132 basal, 82 luminal, 93 HER2+) through univariate and multivariable analyses. Results: In the PAM50 breast cancer data set, PARP1 and 2 expression was altered in 24/58 (41%) HER2+, 32/81 (40%) basal, and 75/324 (23%) luminal A/B breast cancer patients. This correlated with a statistically significant increase in PARP1 protein levels in HER2+ and basal but not luminal breast cancers (p = 0.003, p = 0.027, p = 0.289, respectively). No change in PARP2 protein level was observed. Interestingly, using breast cancer specimens from 307 patients, HER2 positivity correlated with elevated PARP1 expression (p < 0.0001) and was three times more likely than HER2 negative breast cancers to exhibit high PARP1 levels. No significant differences were noted between race, ER status, or PR status for PARP1 expression. Additionally, we found a significant correlation between HER2 status and phospho-p65 expression (p < 0.0001). Lastly, a direct correlation between PARP1 and phospho-p65 (p < 0.0001) was noted. Conclusions: These results indicate a potential connection between HER2, PARP1, and phospho-p65 in human breast tumors. Additionally, these data suggest that the PARPi sensitivity we previously observed in HER2+ breast cancer cells may be due to elevated PARP1 expression. Future testing of PARPi in HER2+ breast cancer patients is warranted.
Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practice
Authors: L. B. Anthony, S. Stafford, M. Cronin, A. Grossman, E. Woltering
Journal: Journal of Clinical Oncology (2004)

4274 Background: Octreotide acetate LAR (LAR) is approved for the control of symptoms from carcinoid syndrome and VIPoma. Recommended LAR doses from the package label are 20 and 30 mg administered monthly. Physicians commonly confront clinical scenarios requiring titration of LAR to doses that control symptoms. We hypothesized that physicians commonly employed doses extending beyond those tested during the registrational period. To test this hypothesis, a physician practice and a patient support group were surveyed. Methods: An internet survey conducted with a yahoo carcinoid patient support group (N=93) (with no individual subject identifiers) and a survey of a physician office practice database using the ICD-9 code of 259.2 (carcinoid syndrome) were conducted (N=309). Results: Of the 93 patients responding to the internet survey, 28 (30%) were on LAR doses > 30 mg / mo as follows: 13 pts, 40 mg; 1 pt, 50 mg: 13 pts, 60 mg; 1 pt, 80 mg. From 50 of the 309 chart reviews from the clinical practice, 36 patients were receiving LAR at doses ranging from 20 mg to 60 mg every 2 to 4 weeks. The most common dose was 30 mg every 4 wks (N=24) followed by 20 mg q 4 wks (N=6). Other doses ranged from 40 mg every 3 wks to 60 mg every 4 wks with 1 patient each at the following doses: 30 mg q 2 wks; 30 mg q 3 wks; 40 mg q 3 wks; 40 mg q 4 wks; 50 mg q 4 wks and 60 mg q Conclusions: Octreotide acetate LAR is prescribed at doses beyond the package label 17% (single physician practice) to 30% (patient survey) of the time. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis
Meeting the educational needs of women with triple-negative breast cancer (TNBC).
Authors: Kathleen Dickerson Swiger, Jocelyn A. Sendecki, Janine E. Guglielmino, Hope S. Rugo, Susan M. Domchek, Carey K. Anders, Carrie Tompkins Stricker, Hillary C.M. Nelson, Arin Ahlum Hanson, Hayley Dinerman, Catherine Creme Henry
Journal: Journal of Clinical Oncology (2015)

e20580 Background: In 2013 Living Beyond Breast Cancer (LBBC) began a comprehensive needs assessment of women with TNBC. Methods: LBBC fielded an online 80-question survey from November 25, 2013-January 10, 2014 to determine specific education and support needs and preferences of women with TNBC. Women with other breast cancer subtypes were included to allow for comparison; subtypes were self-reported. Survey respondents were asked to rate their interest as “not very interested,” “somewhat interested,” or “very interested” in 35 topics. Responses were compared by TNBC status, with p-values adjusted using the false discovery rate (FDR). Results: A total of 2,610 responses from women diagnosed after 2006 were analyzed: 656 (25.1%) identified as TNBC and 1,954 (74.9%) as non-TNBC. Ten topics had statistically significant different rates of interest by TNBC status. Women with TNBC were more likely than those with other subtypes to be very interested in fear of recurrence (77% vs. 65%, p < 0.001), prevention of other illnesses after cancer (75% vs. 68%, p = 0.027), new treatments and the latest research (69% vs. 61%, p = 0.003), connection between breast cancer and the environment (66% vs. 59%, p = 0.021), survivorship care plans (63% vs. 52%, p < 0.001), chemobrain (62% vs. 52%, p < 0.001), clinical trials (38% vs. 27%, p < 0.001), breast reconstruction (36% vs. 27%, p = < 0.001), and parenting issues (20% vs. 17%, p = 0.021). Conclusions: Women with TNBC have preferences for specific education topics. Some differences in topic interests are likely due to the standard treatment regimen for TNBC, which consists of chemotherapy and surgery, with or without radiation, without specifically targeted therapy to reduce risk of recurrence. Healthcare professionals should consider addressing these education topics when evaluating short- and long-term needs of patients with TNBC. Cancer centers and breast cancer organizations should consider developing TNBC-specific educational materials focusing on these topics.
CHANGE IN AORTOMITRAL ANNULAR ANGLE AND ANTERIOR MITRAL VALVE LEAFLET LENGTH AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: IMPLICATIONS FOR TRANSCATHETER MITRAL VALVE REPLACEMENT?
Authors: Abdallah Sanaani, Prakash Harikrishnan, Tanya Dutta, Mala Sharma, Srikanth Yandrapalli, Ryan Kaple, Hasan Ahmad, Cenap Undemir, Alexis Kearns, Angelica Poniros, Cheng Feng, Anna Rozenshtein, Martin Cohen, Joanne Bennett, Steven Lansman, Gilbert Tang
Journal: Journal of the American College of Cardiology (2017)
V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells
Authors: Laura Villani, Rita Campanelli, Gabriella Gaudioso, Valentina Poletto, Elisa Bonetti, Paolo Catarsi, Gabriela Fois, Benedetta G Erba, Margherita Massa, Umberto Magrini, Giovanni Barosi, Umberto Gianelli, Vittorio Rosti
Journal: Blood (2015)